NASDAQ
13.18USD
-0.54 (-3.94%)
We have scored 32 news catalysts on MoonLake Immunotherapeutics (MLTX) over the past 12 months. The biggest single-day move next to one of them came Oct 7, 2025, when MLTX closed +7.2%: “MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX”. Coverage across the window leans negative (average ticker sentiment −0.58). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.1B
P/E
—
EPS
—
Beta
1.04
52W range
5.95-62.75
Day range
13.11–13.62
Open
13.58
Prev close
13.72
Volume
1.2M
Avg volume
1.2M
Dividend
0.00
IPO
2020-10-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about MoonLake Immunotherapeutics — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MLTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
